Orphalan announces acquisition of Orphelia Pharma
Orphalan has strengthened its leadership in rare diseases with the acquisition of Orphelia Pharma, expanding its global footprint and enhancing its portfolio of treatments for severe paediatric neurological and oncological conditions.
Dr Naseem Amin | 12/12/2025 | By Akanki | 215
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy